Skip to main content
. Author manuscript; available in PMC: 2010 Jul 12.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2005 Dec;32(Suppl 2):S358–S383. doi: 10.1007/s00259-005-1960-3

Fig. 5.

Fig. 5

Multimodal imaging for the establishment of imaging-guided experimental treatment strategies. Co-registration of 124I-FIAU, 11C-MET and 18F-FDG PET and MRI before (left column) and after (right column) targeted application (stereotactic infusion) of a gene therapy vector. The region of specific 124I-FIAU retention (68 h) within the tumour after LIPO-HSV-1-tk transduction (white arrowhead) resembles the proposed “tissue dose” of vector-mediated gene expression and shows the signs of necrosis (cross in right column; reduced methionine uptake and glucose metabolism) after GCV treatment. Only such multimodal and multitracer imaging modalities will help us to establish the clinical application of new treatment modalities. (With permission from [1])